David Calvet Canut on Takeda’s HyHub: A Shift Toward Patient-Centered Biologics
David Calvet Canut, Director TFE at UNIR, shared on LinkedIn:
“Takeda’s new HyHub™ system for HYQVIA® represents a significant advancement in patient-centered plasma-derived therapies. By simplifying subcutaneous immunoglobulin infusions, it enhances convenience and treatment adherence—areas where even small innovations can lead to meaningful improvements.
For biotech companies, this serves as a reminder that value creation now extends beyond just the molecule itself. Integration of devices, enhancement of patient experience, and home-based delivery are becoming crucial factors for competitive differentiation and securing reimbursement.
The field of plasma-derived therapies continues to evolve, and these hybrid therapy-plus-device models have the potential to redefine how we design, finance, and scale future biologics.”
Read full paper here.
Stay informed with Hemostasis Today.
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question
-
Oct 20, 2026, 04:04Sadia Kamal: Honored to Receive the Outstanding Abstract Award at the 20th Midwest Platelet Conference
-
Oct 20, 2026, 04:03Yu-Hsuan Chen: One Antibody, Two Diseases from FcRn Biology to Clinical Translation
-
Oct 20, 2026, 03:49Domenico Simone Castiello: Rethinking Prolonged DAPT in Multivessel PCI – Insights from the DAPT-MVD Trial
-
Oct 20, 2026, 03:37Rucha Patil: Scaling POC Diagnostics for Haemophilia A and VWD Across India
-
Oct 20, 2026, 03:31Zena Vexler: Targeting Neutrophil Elastase and NETosis to Mitigate Infection-Triggered Childhood Stroke
-
Oct 20, 2026, 03:24Chaza Alaji: Diagnosing Protein C and Protein S Deficiency